Biotechnology startup Enrich Therapeutics, based In Groton, CT and Worcester, MA, has received a $1.7-million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institute of Health, to work on developing its proprietary single cell isolation platform.
Enrich’s Groton footprint is at the BioCT Innovation Commons.
The Small Business Innovation Research Phase II grant will build on the first phase of an ongoing project, during which Enrich has already completed a prototype design for a non-fluidic technology intended to help isolate cells with the same phenotype.